Cingulate Inc.’s (CING) shares skyrocketed after the company secured a European patent for its groundbreaking ADHD treatment, CTx-1301. This patent covers a significant portion of Europe, including the UK, solidifying Cingulate’s position in the global ADHD market. The company is also preparing to submit a New Drug Application (NDA) to the FDA, marking a crucial step towards bringing this innovative treatment to US patients.